The Organigram leadership team also includes leaders like Chief Revenue Officer Tim Emberg, CFO Derrick West and Chief Legal Officer Helen Martin. The company has also made some recent additions to the team, such as Senior VP of Marketing Megan McCrae and VP of Innovation Borna Zlamalik. Goldenberg also highlighted VP of Operations Nathalie Batten, who is helping to drive lower costs and better yields at the company’s Moncton, New Brunswick facility.
The Organigram leadership team also includes leaders like Chief Revenue Officer Tim Emberg, CFO Derrick West and Chief Legal Officer Helen Martin. The company has also made some recent additions to the team, such as Senior VP of Marketing Megan McCrae and VP of Innovation Borna Zlamalik. Goldenberg also highlighted VP of Operations Nathalie Batten, who is helping to drive lower costs and better yields at the company’s Moncton, New Brunswick facility.
Canadian Operations
Organigram’s cultivation facility in Moncton currently has an annual capacity of 40,000 kilograms, but the company is investing $38 million into the phase 4C expansion of the facility. This expansion initiative will increase annual capacity to 70,000 kilograms.
This facility is also home to extraction and pre-roll operations, as well as a center of excellence where the company is collaborating with the BAT team on product development.
In the spring, Organigram acquired Edibles & Infusions Corporation (EIC). As a result, the company now has a facility in Winnipeg, Manitoba. This facility produces Organigram’s gummy products, including Shred branded gummies and CBD gummies under the recently announced Monjour brand. The company will also be moving the production of its Edison JOLTS lozenges to its derivatives facility in Winnipeg.
Continued Momentum
The company announced its Q4 results near the end of November. With strong momentum coming out of 2021, Organigram announced that it expects revenue to be higher in Q1 fiscal 2022 than in Q4 fiscal 2021. The company is growing its top line and improving its margins, according to Goldenberg. Organigram expects to reach positive EBITDA by the end of the fiscal year 2022.
Market share is one of the most important metrics for the company. In the middle of November, Organigram had a 7.9 percent market share, a strong indicator of consumer connection to the company’s brands, according to Goldenberg. Launching new SKUs is also an important goal for the company. In 2021, the company launched more than 100 new SKUs, and it continues to have an active product innovation pipeline.
On the brand side, the company tracks metrics like customer loyalty and net promoter score to ensure it is continuously connecting with cannabis consumers.
Organigram’s biggest challenge going into 2022 will be keeping up with demand. Its $38 million expansion project will help it to meet that demand. The company is also investing in in-store budtender education and its online platform to better connect with its consumers. As the company grows, it will continue to search for opportunities to innovate and create differentiation in the competitive cannabis space.
